Skip to main content
AROA BIOSURGERY LIMITED logo

AROA BIOSURGERY LIMITED — Investor Relations & Filings

Ticker · ARX ISIN · NZARXE0001S1 ASX Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2020-07-22 Director's Dealing
Country AU Australia
Listing ASX ARX

About AROA BIOSURGERY LIMITED

https://aroa.com/

Aroa Biosurgery Limited specializes in the development and commercialization of regenerative medical devices for wound healing and soft tissue reconstruction. The company’s core technology is the AROA ECM platform, a proprietary extracellular matrix derived from ovine forestomach tissue. This scaffold-based technology is engineered to facilitate host cell infiltration and promote new blood vessel formation, supporting the body's natural healing process. The product portfolio includes Endoform for chronic and acute wound management, Myriad for complex surgical applications, and Symphony for skin substitute procedures. Additionally, the company manufactures the Ovitex and Ovitex PRS reinforced tissue matrices for hernia repair and breast reconstruction. These solutions target clinical needs in advanced wound care and surgical specialties by providing biological scaffolds that integrate into host tissue.

Recent filings

Filing Released Lang Actions
Securities Dealing Policy 7 pages 347.2KB
Director's Dealing Classification · 95% confidence The document is a detailed policy titled 'Securities Dealing Policy' for Aroa Biosurgery Limited. It outlines rules and restrictions on trading the company's securities by directors, employees, and associated persons, including insider trading prohibitions, blackout periods, notification and consent requirements, and exceptions. It also includes a form for notification to deal in securities. The content focuses on governance and compliance related to securities trading by insiders rather than financial results, audit, or other report types. This type of document fits best under 'Director's Dealing' (DIRS) as it relates to insider trading policies and reporting of personal share transactions by company directors and executives. The document length is substantial and contains the full policy, not just an announcement or summary, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Therefore, the classification is DIRS with high confidence.
2020-07-22 English
Distribution Schedule 1 page 111.5KB
Major Shareholding Notification Classification · 95% confidence The document is titled 'Analysis of Holdings Aroa Biosurgery Limited' and provides a detailed breakdown of shareholdings by range and percentage. It lists security classes and the number of holders and units for each range. There is no indication of this being a full financial report, audit, or management discussion. It is a notification of share ownership distribution, which aligns with a Major Shareholding Notification. The document length is short and focused solely on shareholding data, fitting the MRQ category rather than a general regulatory filing or other report types.
2020-07-22 English
Top 20 Shareholders 2 pages 122.3KB
Major Shareholding Notification Classification · 95% confidence The document lists the top 20 holdings of Aroa Biosurgery Limited as of a specific date (22-07-2020), detailing shareholder names, security classes, and percentage ownership. It is a factual summary of major shareholders and their holdings, without financial statements, management commentary, or regulatory announcements. This type of document fits the definition of a Major Shareholding Notification (MRQ), which reports changes or current status of significant share ownership levels. The document length is short and focused solely on shareholding data, not a full report or announcement of a meeting or vote.
2020-07-22 English
Pre-Quotation Disclosure Statement 3 pages 128.5KB
Capital/Financing Update Classification · 95% confidence The document is titled 'PRE-QUOTATION DISCLOSURE' and relates to the initial public offering (IPO) and official quotation of shares on the ASX. It details the close of the offer, share issuance, escrow arrangements, ASX waivers, and share capital structure changes. There is no financial performance data or comprehensive financial statements, nor is it an annual or interim report. The content focuses on capital raising and share issuance activities associated with the IPO. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on fundraising and capital structure changes related to the IPO.
2020-07-22 English
Appointment of Company Secretary 1 page 150.9KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 23 July 2020 regarding the appointment of a new Company Secretary at Aroa Biosurgery Limited. It contains no financial data, no report or presentation, no voting results, no legal proceedings, no capital changes, and no earnings information. The content is focused solely on management/board changes, specifically the appointment of a company secretary, which is a senior management role. The document length is 2632 characters, which is short and clearly an announcement rather than a full report. Therefore, the appropriate classification is Board/Management Information (MANG).
2020-07-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.